Which way you will choose?
Supply chain, the connection between the laboratory and the market, needs a serious revision
Most pharma companies have complex supply chains that are not utilised, inefficient and unequipped to cope with the kind of products coming down the production line.This new report predicts that in order to meet the demands of a fast growing market and the shift from patient to outcome, the pharma supply chain will need to undergo a radical revision.
Many forces are reshaping the atmosphere of the operating industry and imposing the need for a different kind of supply chain
When we come to 2020, the diversity of products and their therapy methods with shorter product lifecycles; new ways for valuation, confirming and monitoring pharmaceuticals; increasing the significance on outcomes; new ways of delivering healthcare especially as it oriented to community plus, accessing to information on patients will become as important as the products themselves; the growing importance of developing markets; a greater public examination impacting the ability to manage risk and compliance; and harder environmental controls and regulations will push companies to strategically re-valuate their supply chain.
Promptly access to growing technologies will increase the efficiency of production and distribution
New techologies are aiming to help pharmaceutical firms to produce larger and more complicated medicines and on the other hand, to distribute them and also to accelerate the connection with the patient and getting closer than before.
Cooperation between the parties that takes place in the healthcare assurance, will provide an efficient industry more than ever
Supply chains that provides the delivery, production and design of the medical devices and pharmaceuticals; will help all stakeholders to see the full picture, to plan well directed and cost effective